Lutetium-177 Supply Market Report 2026

Lutetium-177 Supply Market Overview

• Lutetium-177 Supply market size has reached to $1.4 billion in 2025 • Expected to grow to $2.94 billion in 2030 at a compound annual growth rate (CAGR) of 15.9% • Growth Driver: Rising Prevalence Of Cancers Fueling The Market Growth Due To Increasing Life Expectancy • Market Trend: Development Of Multi-Isotope Production Capabilities In Nuclear Medicine • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Lutetium-177 Supply Market?

Lutetium-177 supply refers to the production, processing, and distribution of the radioactive isotope Lutetium-177 used in targeted radionuclide therapy and nuclear medicine applications. It is produced through nuclear reactor or cyclotron-based methods and is designed to deliver localized radiation for therapeutic procedures while supporting precision treatment approaches. It requires specialized handling, quality control, packaging, and transportation infrastructure to ensure safety, stability, and regulatory compliance. The main production methods of lutetium-177 supply include reactor produced lutetium one hundred seventy-seven, cyclotron produced lutetium one hundred seventy-seven, carrier added lutetium one hundred seventy-seven, and non carrier added lutetium one hundred seventy-seven. Reactor produced lutetium one hundred seventy-seven refers to a medical radioisotope used in targeted radionuclide therapy, especially for oncology applications. These supplies are distributed through direct supply agreements, radiopharmaceutical distributors, hospital procurement channels, and research supply networks. The key applications of neuroendocrine tumor treatment, prostate cancer treatment, bone metastasis treatment, clinical research applications, and others, while the end-users includes hospitals, specialty cancer clinics, research institutes, radiopharmaceutical companies, and diagnostic centers.

What Is The Lutetium-177 Supply Market Growth Forecast?

The lutetium-177 supply market size is expected to see rapid growth in the next few years. It will grow to $2.94 billion in 2030 at a compound annual growth rate (CAGR) of 15.9%. The growth in the forecast period can be attributed to growing demand for precision oncology treatments, increasing expansion of commercial radiopharmaceutical manufacturing capacity, rising investments in advanced isotope production technologies, increasing development of novel lutetium-177 therapeutic applications, growing establishment of regional isotope supply networks. Major trends in the forecast period include increasing expansion of reactor based isotope production capacity, growing focus on high purity lutetium-177 supply chains, rising investments in radiopharmaceutical logistics infrastructure, increasing adoption of non carrier added lutetium-177 production methods, growing emphasis on regulatory compliant isotope transportation networks.

Global Lutetium-177 Supply Market Segmentation

1) By Production Method: Reactor Produced Lutetium One Hundred Seventy-Seven; Cyclotron Produced Lutetium One Hundred Seventy-Seven; Carrier Added Lutetium One Hundred Seventy-Seven; Non Carrier Added Lutetium One Hundred Seventy-Seven 2) By Distribution Channel: Direct Supply Agreements; Radiopharmaceutical Distributors; Hospital Procurement Channels; Research Supply Networks 3) By Application: Neuroendocrine Tumor Treatment; Prostate Cancer Treatment; Bone Metastasis Treatment; Clinical Research Applications; Other Applications 4) By End User: Hospitals; Specialty Cancer Clinics; Research Institutes; Radiopharmaceutical Companies; Diagnostic Centers Subsegments: 1) By Reactor Produced Lutetium One Hundred Seventy-Seven: Direct Neutron Activation Reactor Produced Lutetium One Hundred Seventy-Seven; Indirect Reactor Produced Lutetium One Hundred Seventy-Seven; High Purity Reactor Produced Lutetium One Hundred Seventy-Seven; Medical Grade Reactor Produced Lutetium One Hundred Seventy-Seven 2) By Cyclotron Produced Lutetium One Hundred Seventy-Seven: Proton Irradiation Cyclotron Produced Lutetium One Hundred Seventy-Seven; High Specific Activity Cyclotron Produced Lutetium One Hundred Seventy-Seven; Research Grade Cyclotron Produced Lutetium One Hundred Seventy-Seven; Commercial Scale Cyclotron Produced Lutetium One Hundred Seventy-Seven 3) By Carrier Added Lutetium One Hundred Seventy-Seven: High Activity Carrier Added Lutetium One Hundred Seventy-Seven; Reactor Derived Carrier Added Lutetium One Hundred Seventy-Seven; Clinical Grade Carrier Added Lutetium One Hundred Seventy-Seven; Industrial Use Carrier Added Lutetium One Hundred Seventy-Seven 4) By Non Carrier Added Lutetium One Hundred Seventy-Seven: High Specific Activity Non Carrier Added Lutetium One Hundred Seventy-Seven; Medical Grade Non Carrier Added Lutetium One Hundred Seventy-Seven; Therapeutic Use Non Carrier Added Lutetium One Hundred Seventy-Seven; Research And Diagnostic Non Carrier Added Lutetium One Hundred Seventy-Seven

What Is The Driver Of The Lutetium-177 Supply Market?

The rising prevalence of cancer is expected to propel the growth of the lutetium-177 supply market going forward. Cancer is a group of diseases where abnormal cells grow uncontrollably, invade tissues, and can spread to other parts of the body. The cancer prevalence is increasing due to aging population, as advanced age is the most significant risk factor for developing most types of cancer, with the majority of cases occurring in individuals over 65 years old. Lutetium-177 Supply enables targeted cancer therapies that deliver precise radiation to tumor cells while minimizing damage to healthy tissues, improving treatment outcomes for neuroendocrine tumors and metastatic prostate cancer, and advancing personalized oncology care worldwide. For instance, in February 2024, according to the World Health Organization, a Switzerland-based international organization, over 35 million new cancer cases are predicted in 2050, a 77% increase from the estimated 20 million cases in 2022. Therefore, the rising prevalence of cancer is driving the growth of the lutetium-177 supply industry.

Key Players In The Global Lutetium-177 Supply Market

Major companies operating in the lutetium-177 supply market are Novartis AG; Telix Pharmaceuticals Limited; Bayer AG; Cardinal Health Inc.; Siemens Healthineers AG; Curium International Trading B.V.; Eckert & Ziegler SE; NRG PALLAS B.V.; State Atomic Energy Corporation Rosatom; Framatome SAS; BWX Technologies Inc.; National Centre for Nuclear Research Radioisotope Centre POLATOM; Isotopia Molecular Imaging Ltd.; Nusano Inc.; ITM Isotope Technologies Munich SE

Global Lutetium-177 Supply Market Trends and Insights

Major companies operating in the lutetium-177 supply market are focusing on developing advanced initiatives, such as large-scale commercial radioisotope production plaforms to enhance the availability, reliability, and scalability of medical isotopes used in targeted cancer therapies and diagnostic imaging applications. Large-scale commercial radioisotope production platforms are advanced manufacturing systems designed to produce medical isotopes in high volumes through scalable irradiation and purification processes, helping ensure a stable, reliable, and continuous supply of therapeutic and diagnostic isotopes for cancer treatment and nuclear medicine applications. For instance, in January 2025, Nusano Inc., a US-based radioisotope development company, launched commercial isotope operations and announced a lutetium-177 supply agreement with GlyTherix. The initiative supports the production and supply of Lu-177 for targeted radiopharmaceutical therapies and also provides future access to isotopes including actinium-225, zirconium-89, lead-212, and terbium-161. Nusano’s flagship facility in West Valley City, Utah, is designed to simultaneously produce up to 12 different radioisotopes and ultimately support a portfolio of more than 25 isotopes for life sciences applications. The platform enhances isotope supply reliability for clinical trials and commercial therapeutic programs, particularly for oncology-focused radiopharmaceuticals targeting aggressive cancers through precision molecular therapies.

What Are Latest Mergers And Acquisitions In The Lutetium-177 Supply Market?

In July 2023, ITM Isotope Technologies Munich SE, a Germany-based radiopharmaceutical biotechnology company that specializes in manufacturing of non-carrier-added Lutetium-177, partnered with POINT Biopharma Global Inc. to expand their global supply agreement for non-carrier-added Lutetium-177 (n.c.a. ^177Lu). With this partnership, ITM Isotope Technologies Munich SE and POINT Biopharma Global Inc. aim to strengthen the clinical and potential future commercial development of ^177Lu-based radiopharmaceuticals across POINT’s oncology pipeline by ensuring a scalable and reliable supply of high-purity medical radioisotopes. POINT Biopharma Global Inc. is a US-based radiopharmaceutical company that discovery, development, and commercialization of targeted radioligand therapies for cancer treatment.

Regional Outlook

North America was the largest region in the lutetium-177 supply market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Lutetium-177 Supply Market?

The lutetium-177 supply market consists of sales of radiopharmaceutical isotopes, radioactive source materials, isotope processing equipment, shielding containers, and related nuclear medicine products. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Lutetium-177 Supply Market Report 2026?

The lutetium-177 supply market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the lutetium-177 supply industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.